Shilpa Medicare
Shilpa Medicare Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
From Shilpa Medicare's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth.
- Formulation business growing robustly, with 104% quarter-on-quarter growth excluding licensing income.
- Launches like NorUDCA and transdermal Rotigotine to boost revenues.
- Biologics and Formulation segments anticipated to drive higher growth; API segment to grow steadily.
- Increased utilization and new oral solid line at formulation plant to support revenue ramp-up.
- Oncology business expected to grow with resolved product validations and increased capacity.
- CDMO peptide facility launching with ~INR40 crore capex, expecting inquiries and scale-up.
- Licensing income stable at ~INR150 crores annually, with quarter-to-quarter variations normal.
- Albumin product commercialization anticipated in India by FY '28, adding new revenue streams.
- Capacity expansions and productivity improvements planned to increase asset turnover and output.
Profitability & Margins
See what Shilpa Medicare said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
- Investment in a new oral solid formulation line recently commissioned to support upcoming launches and generate additional revenues in FY '27 (Page 15).
- Significant past capex completed; current focus is on execution, scaling, and maximizing ROCE from existing investments (Page 6).
- Capex of about INR 87 crores incurred during Q3 FY '26, with expectation to mainly fund capex through internal accruals (Page 6).
- No long-gestating investments planned; peptide investment is strategic with focus on timely patent expiries (Page 13).
- Incremental capex aimed at increasing production efficiency, capacity utilization, and supporting ongoing product development (Pages 15-16).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shilpa Medicare said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- NorUDCA launch has been very successful, exceeding expectations with a strong order book as of Q3 FY26.
- Good traction in NorUDCA is noted with an expanding order book from the three marketing partners.
- For oncology and other products, specific order book numbers were not disclosed due to confidentiality.
- Formulation segment shows stable base revenue, with Europe at ~INR73 crores indicating a steady order flow.
- The company expects increased ramp-up and order inflow from new product launches and capacity expansions in FY27.
- Partnerships for ADC biosimilars and other product pipelines are expected to contribute to future order books starting FY27.
Shilpa Medicare — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹437 Cr, net profit ₹108 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shilpa Medicare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- OneSource Specialty Pharma Ltd (Q3 FY26)
OneSource Specialty Pharma is aggressively investing in capacity expansion with over INR 700 crores (approximately $100 million) planned for flagship site…
- Mankind Pharma Ltd (Q3 FY26)
Overall domestic prescription business growth for Q3 was 9%+ and 8.2% for 9 months (excluding OTC), indicating steady growth. Key concall takeaways from…
- Gland Pharma (Q3 FY26)
Investments of INR 2,000 crores over next 5 years, including Brownfield expansions, BFS lines, and ophthalmic lines, to enhance capacity and drive volume/value…
- Sanofi India Ltd (Q3 FY26)
Diabetes portfolio is growing consistently, with insulin segment showing 6% full-year growth and double-digit growth in Q4 2025. Key concall takeaways from…
Frequently Asked Questions
What were Shilpa Medicare Q3 FY26 results?
FY '27 expected to have strong growth momentum, building on Q3's solid 30% growth. Highest ever quarterly revenue of INR411 crores in Q3 FY '26, growing 28% YoY; 9 months revenue at INR1,110 crores, up 14%.
What is Shilpa Medicare share price analysis?
Shilpa Medicare currently shows a neutral. The stock trades at a P/E of 56.0 with a market cap of ₹15,939 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shilpa Medicare planning capital expenditure?
New peptide capacity planned with a capex of around INR 40 crores to cater to growing GLP-1 peptide demand and CDMO opportunities (Page 13).
Keep Shilpa Medicare on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.